Monitor for data presentation at the World Parkinson Congress in May 2026, which could provide early efficacy signals in a devastating disease with no approved disease-modifying therapies. Positive results could attract partnership interest or boost valuation.
Price Chart
Executive Summary
Tiziana Life Sciences announced that a late-breaking poster on its Phase 2a clinical trial of intranasal foralumab in Multiple System Atrophy (MSA) has been accepted for presentation at the 7th World Parkinson Congress in May 2026. The trial is ongoing and enrolling up to 10 patients, with primary endpoints focused on neuroinflammation and clinical symptom changes.
Key Facts
- Late-breaking poster on Phase 2a study of intranasal foralumab in MSA accepted for presentation at 7th World Parkinson Congress (May 24-27, 2026)
- TILS-025 trial is first clinical investigation of intranasal anti-CD3 therapy in MSA
- Phase 2a, open-label trial enrolling up to 10 subjects with MSA
- Primary endpoints: changes in microglial activation (via TSPO PET imaging) and MDS-UMSARS scores
- Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development
Financial Impact
No direct financial impact disclosed; potential long-term value from clinical progress in high-unmet-need neurodegenerative disease
Risk Factors
- Small trial size (n=10) limits statistical power
- Early-phase study with no efficacy or safety data disclosed in this filing
- Forward-looking statements subject to risks and uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-043198 |
| Document: ea028624901ex99-1.htm | 0001213900-26-043198 |
| Document: 0001213900-26-043198-index-headers.html | 0001213900-26-043198 |
| Document: 0001213900-26-043198-index.html | 0001213900-26-043198 |
| Document: 0001213900-26-043198.txt | 0001213900-26-043198 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8800 (−12.87%) |
Oct 16, 2026 11d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8800 (+12.87%) |
Oct 16, 2026 11d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8800 (−16.19%) |
Sep 30, 2026 27d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8800 (−20.72%) |
Sep 28, 2026 29d ago | 6-K | $0.9800 $0.8850 | ▼ −9.69% | ▼ −9.66% | $0.8800 (−10.20%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8800 (−2.72%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8800 (−9.28%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8800 (−9.28%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8800 (−23.48%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8800 (−9.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers